What were the key takeaways from PAVmed’s earnings call?

What is PAVmed's latest dividend and current dividend yield?

What were the key takeaways from PAVmed's earnings call?

What factors drove the changes in PAVmed's revenue and profit?

What is the revenue and EPS growth rate for PAVmed year over year?

What is PAVmed's gross profit margin?

What does PAVmed do and what are its main business segments?

What guidance did PAVmed's management provide for the next earnings period?

- **Lucid Milestone**: Medicare coverage endorsement for EsoGuard, $27M capital raise extends runway to 2026.
- **Veris Growth**: Implantable device on track for 2026 FDA submission, expanding commercial reach with clinical support services.
- **New Technology**: Breakthrough endoscopic imaging partnership with Duke/UNC nearing definitive agreement.
- **Financial Stability**: Restructured debt, cash flow breakeven with $446K non-GAAP loss Q3.

**【CEO Summary Section】**
- **Corporate Restructuring Progress**: Completed debt restructuring, nearing final steps to stabilize balance sheet and enable subsidiary growth under shared services model.
- **Lucid Highlights**: 
  - EsoGuard Q3 revenue $1.2M, test volume 2,800, consistent with target range.
  - Medicare coverage endorsement from experts, expected near-term approval.
  - $27M capital raise extends runway to 2026.
- **Veris Developments**: 
  - Commercial launch at OSU Cancer Center with 1,000-patient registry target.
  - Implantable device development on track for 2026 FDA submission.
  - New AI-based clinical decision tools and clinical support services in development.
- **New Technology Partnership**: Finalizing license agreement with Duke/UNC for breakthrough endoscopic imaging technology for esophageal precancer detection.

**【CFO Financial Commentary】**
- **Financial Restructuring**: Deconsolidated Lucid from PAVmed financials, Series C preferred stock restructuring reduced debt burden.
- **Cash Flow Management**: Q3 cash burn $900K, fully funded by Veris-specific financings ($2.4M Q1, $2.5M Q2).
- **Equity Method Investment**: $32M equity value in Lucid (23% ownership), marked-to-market quarterly.
- **Non-GAAP Loss**: $446K Q3, driven by Veris device development costs.

**【Q&A Key Highlights】**
- **Implantable Device Regulatory Path**: 510(k) submission planned for 2026, requiring only skin-based clinical study for equivalence to predicate device.
- **Commercial Expansion Strategy**: 
  - Begin outreach to new cancer centers Q1 2026 with clinical support services offering.
  - AI-based risk stratification tools to be co-developed with OSU.
- **Duke Imaging Technology**: Definitive license agreement expected shortly, 510(k) regulatory pathway with modest clinical requirements.

PAVmed Inc. (PAVM) Q3 2025 Earnings Call Transcript

- **Medicare Coverage Imminent**: CAC meeting in September is a final step toward Medicare approval, with experts expected to validate EsoGuard's clinical utility. Draft LCD anticipated soon after, final approval by early 2026.
- **Revenue Growth Accelerating**: Q2 revenue up 40% sequentially to $1.2 million, driven by 2,756 tests. 30% of adjudicated claims approved at $1,786 per test, signaling strong reimbursement potential.
- **Strategic Partnerships**: Hoag Health System partnership expands testing to 200 primary care physicians. Fire departments and municipalities contribute to steady pipeline growth.
- **Profitability Pathway**: 90% contribution margin per test with fixed lab costs of $1.2 million/quarter. Scaling capacity allows rapid expansion without capital investment.
- **Commercial Momentum**: First commercial coverage policy with Highmark, with regional plans engaging positively. Medicare coverage will unlock 40-50% of addressable market.

**【CEO Summary Section】**
- **Upcoming Medicare Milestone**: The September 4 CAC meeting is a critical step toward securing Medicare coverage for EsoGuard, with high confidence in a positive outcome. The meeting will involve multiple MACs and expert opinions on clinical utility.
- **Test Volume Growth**: Q2 2025 saw 2,756 tests performed, within the target range of 2,500-3,000, and revenue of $1.2 million, a 40% sequential increase. The partnership with Hoag Health System aims to expand comprehensive testing programs across 200 primary care physicians.
- **Commercial Payer Progress**: Secured Highmark Blue Cross Blue Shield coverage in Upstate New York, with ongoing engagements with regional and national plans. Medicare coverage is expected to accelerate commercialization efforts.
- **Market Expansion**: Targeting Medicare patients (40-50% of the 30 million guideline-eligible population) through digital targeting and partnerships in high-concentration states like Florida and Texas.

**【CFO Financial Commentary】**
- **Financial Health**: Ended Q2 with $31.1 million in cash, a $10.3 million quarterly burn rate, and $16.1 million from a public offering. Non-GAAP net loss was $9.9 million, improving sequentially and year-over-year.
- **Revenue Recognition**: 17% of Q2 billed tests ($6.9 million) were recognized as revenue ($1.2 million), with 65% of claims adjudicated and 30% approved at an average of $1,786 per test.
- **Cost Efficiency**: Lab fixed costs are stable at $1.2 million per quarter, with a 90% contribution margin per test. Scaling is expected to drive profitability without significant capital investment.

**【Q&A Highlights】**
- **Medicare Timeline**: Anticipate a draft LCD shortly after the CAC meeting, with final approval expected by early 2026. A year of backlogged claims will be submitted post-approval.
- **Commercial Pipeline**: Regional Blue Cross Blue Shield plans are engaging positively, with Highmark's coverage serving as a precedent. Medicare coverage will complement, not replace, commercial efforts.
- **Capacity and Scaling**: Laboratory and manufacturing capacity can handle fivefold growth with minimal incremental costs, enabling rapid scaling post-approval.
- **Burn Rate Management**: No plans to reduce test volume or burn rate, focusing instead on accelerating commercialization as coverage expands.

PAVmed (PAVM)-13 Aug 25-2025 Q2 Earnings call transcript

- **Lucid Momentum**: $800K Q1 revenue, Medicare coverage pending, and $16.1M capital raise extend runway for 2026 milestones.
- **Veris Breakthrough**: Implantable monitor development restarts with FDA engagement; OSU partnership targets 1,000+ patient enrollments post-EHR integration.
- **Biopharma Expansion**: Leveraging clinical trial expertise to pursue oncology/assets, with subsidiary-specific capital raises planned.
- **Financial Strength**: PAVmed's $47M Lucid equity stake and reduced liabilities ($25M) support strategic flexibility.

**【CEO Opening Remarks】**
- PAVmed operates as a diversified life sciences parent company with independently financed subsidiaries (Lucid, Veris, PMX) under a shared services model.
- **Lucid Highlights**: Q1 2025 revenue of $800K, test volume of 3,034 (upper end of target range). Secured $16.1M through a public offering, extending cash runway into 2026. Awaiting Medicare coverage response for e-cigar test, with commercial momentum in concierge and employer channels expected to boost H2 revenue.
- **Veris Progress**: Restarted development of implantable physiologic monitor with FDA engagement. Signed OSU commercial partnership for ≥1,000 patient enrollments in first year, pending EHR integration completion.
- **Biopharma Expansion**: Exploring partnerships to leverage PAVmed's clinical trial expertise and shared services model, targeting oncology and cardio-metabolic assets in late preclinical/Phase 1 stages.

**【CFO Financial Update】**
- **Balance Sheet**: PAVmed holds $47M equity method investment in Lucid (29% ownership), post-debt exchange reducing liabilities by $25M. Series C preferred stock conversion could add 23M shares at $1.07/share.
- **Lucid Performance**: 82% share price gain QoQ, contributing $21M to PAVmed's Q1 GAAP net income of $18.6M (EPS $1.28). Lucid's standalone cash of $40M supports its Medicare coverage pursuit.
- **Operating Expenses**: Q1 non-GAAP OpEx $4.4M, stable vs. prior quarters, funded by NIH grants ($900K) and Veris financing ($2.4M).

**【Q&A Key Takeaways】**
- **Veris Platform Feedback**: OSU pilot met all metrics, with enthusiasm for the implantable monitor launch. No major platform changes needed; implementation lessons will inform broader rollouts.
- **Biopharma Financing**: Subsidiaries (e.g., Veris) will raise dedicated capital, aligning with PAVmed's decentralized model. Access to private and public capital for biopharma assets is expected.
- **Market Volatility Impact**: PAVmed's strategic investor base and strong balance sheet mitigate funding risks, evidenced by Q1 Veris financing and Lucid's capital raise success.

PAVmed Inc. (PAVM) Q1 2025 Earnings Call Transcript

- **Lucid Momentum**: 45% QoQ test volume growth, first commercial insurance coverage, and NCCN guideline inclusion drive EsoGuard adoption.
- **Veris Breakthrough**: $35M pre-money valuation financing; FDA-cleared implantable monitor on track for late 2025 submission. Strategic partnership with Ohio State to expand cancer care platform.
- **PortIO Innovation**: Gen 1 device completes first-in-human study; Gen 2 in development with FDA de novo pathway for 2026 launch.
- **Financial Stability**: Restructured debt, $2.4M Veris financing, and NIH grants extend cash runway for key milestones.


**【CEO Opening Remarks】**
- **Strategic Restructuring Complete**: PAVmed now operates as a diversified life sciences company with independently financed subsidiaries (Lucid, Veris, PMX). Deconsolidation of Lucid and debt restructuring achieved NASDAQ compliance.
- **Lucid Highlights**: Q4 2024 EsoGuard revenue $1.2M (45% QoQ growth), 4,042 tests booked. Secured first commercial insurance coverage with Highmark and NCCN guideline inclusion. Concierge medicine contracts exceed 20.
- **Veris Progress**: $2.4M private placement at $35M pre-money valuation; $1.8M NIH grant for implantable physiologic monitor. FDA clearance submission expected late 2025/early 2026. Pilot with Ohio State extended to April; strategic partnership imminent.
- **PortIO Updates**: $42M pre-money valuation discussions with investors. Gen 1 device completed first-in-human study; Gen 2 in development. FDA de novo pathway anticipated with 50-80 patient IDE study.

**【CFO Financial Overview】**
- **Q4 2024 Financials**: Non-GAAP loss $688K (offset by $900K NIH grant). Operating expenses $5.2M (including $700K stock-based comp). GAAP net income $1.3M ($0.12 diluted EPS). Cash runway extended beyond key reimbursement milestones.
- **Balance Sheet Strength**: $31.3M equity method investment in Lucid (marked-to-market at $0.82/share). Preferred equity increased by $25M post-debt exchange. Unvested RSAs: 17.5M shares.

**【Q&A Key Takeaways】**
- **Veris-Ohio State Partnership**: First major commercial engagement with 3rd largest cancer center. Commitment to enroll substantial patients, registry data collection, and AI-driven clinical decision support tools. Implantable device FDA clearance expected late 2025; strategic partnership to serve as industry benchmark.
- **FDA Timeline Clarity**: Implantable monitor avoids full clinical trial via skin study validation. PortIO Gen 1 IDE study to begin within 18 months; Gen 2 swap-in during trial for faster commercial launch.
- **Market Differentiation**: Veris' oncology-specific RPM platform and proprietary implantable device create competitive moat. No direct competitors in cancer-focused remote monitoring.


Actual		-50.4224	-54.3011	-77.573	-77.573	-73.6943	-59.4	-78.6	-35.7	193.1005	3.968	10.2	-22.2	-8.7
Forecast		-46.5438	-38.7865	-62.0584	-78.8658	-80.1587	-48.8934	-50.2	-43.6	59.25	-3.3	-10.5	-3.9	-5.1	-5.4
Surprise	0.00%	-8.33%	-40.00%	-25.00%	+1.64%	+8.06%	-21.49%	-56.57%	+18.12%	+225.91%	+220.24%	+197.14%	-469.23%	-70.59%	0.00%

PAVM

PAVM fundamentals

PAVM Q4 2025 Earnings Preview

Earnings Call

You can ask Aime

PAVM

PAVM fundamentals

PAVM Q4 2025 Earnings Preview

Earnings Call

PAVM Earnings Call Summary for Q4/20258:30 AM on Mar 30, 2026

PAVM Earnings Call Summary for Q3/20258:30 AM on Nov 13, 2025

PAVM Earnings Call Summary for Q2/20258:30 AM on Aug 13, 2025

PAVM Earnings Call Summary for Q1/20258:30 AM on May 15, 2025

PAVM Earnings Call Summary for Q4/20248:30 AM on Mar 25, 2025

You can ask Aime